Journal of Shanghai Jiao Tong University (Medical Science) >

2022 , Vol. 42 >Issue 5: 617 - 623

DOI: https://doi.org/10.3969/j.issn.1674-8115.2022.05.009

Clinical research

Relationship between histopathological features, Ki-67 expression and prognosis of conjunctival melanoma

  • Tianyu ZHU ,
  • Chunyan ZONG ,
  • Shiqiong XU ,
  • Shengfang GE ,
  • Xianqun FAN ,
  • Renbing JIA
Expand
  • 1.Department of Ophthalmology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China
    2.Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai 200011, China
JIA Renbing, E-mail: renbingjia@sjtu.edu.cn.

Received date: 2022-03-19

  Accepted date: 2022-05-25

  Online published: 2022-05-28

Supported by

The Science and Technology Commission of Shanghai(20DZ2270800);National Facility for Translational Medicine (Shanghai)(TMSZ-2020-206)

Fold

Abstract

Objective

·To investigate the relationship between histopathological features, Ki-67 expression and prognosis of conjunctival melanoma (CoM).

Methods

·Thirty-six patients with histopathologically confirmed CoM admitted to the Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine between August 2008 and September 2020 were selected, and their clinical characteristics and histopathological features data were collected to analyze their clinicopathological characteristics, Ki-67 expression and prognostic relationships.

Results

·Thirty-six patients with CoM were included in this study, including 26 males and 10 females, with a mean age of 57.81 (31?82) years. The site of onset was located in the lacrimal caruncle in 11 cases (30.6%), the fornix in 8 cases (22.2%), and the palpebral conjunctiva in 15 cases (41.7%). One patient (2.8%) had T1 stage disease, 12 (33.3%) had T2 stage disease, and 23 (63.9%) had T3 stage according to the American Joint Committee on Cancer (AJCC) 8th edition staging system. During the follow-up period, local recurrence was observed in 16 patients (44.4%), distant metastases in 17 patients (47.2%) and 16 patients (44.4%) died of disease. The Breslow thickness of CoM tumors was 4.05 (0.2?15.9) mm, with 18 cases (50.0%) >4 mm. Ulceration and regression were observed in 13 cases (36.1%) and 7 cases (19.4%), respectively. Tumor-infiltrated lymphocytes (TILs) were rated as “brisk” in 4 patients (11.1%) and “nonbrisk” in 26 patients (72.2%). Three patients (8.3%) had perineural invasion and 8 patients (22.2%) had vascular invasion. Thirty-five cases (97.2%) were in the vertical growth phase, and microscopic satellitosis was observed in only one case (2.8%). Regarding the histological type, 18 cases (50.0%) were superficial spreading, 12 (33.3%) were nodular, 4 (11.1%) were lentiginous, and 2 were unknown. Ki-67 index>20% was observed in 14 patients (38.9%). Breslow thickness >4 mm indicated high risk of local recurrence (P=0.049) and disease-related death of CoM (P=0.049). Histological ulceration and regression were risk factors for local recurrence (P=0.030) and distant metastasis (P=0.046), respectively. In addition, Ki-67 index was related with local recurrence (P=0.016). Spearman correlation analysis showed that Ki-67 index was positively correlated with local recurrence (P=0.433). CoM patients with a Ki-67 index higher than 20% had a higher risk of local recurrence [hazard ratio (HR) 3.61, 95% confidence interval (CI) 1.26?10.28, Log-rank P=0.011].

Conclusion

·Histopathological features and Ki-67 expression of CoM can be used to predict patient prognosis and help guide clinical treatment.

Key words： conjunctival neoplasms; melanoma; clinicopathology; Ki-67; recurrence; prognosis

Cite this article

Tianyu ZHU , Chunyan ZONG , Shiqiong XU , Shengfang GE , Xianqun FAN , Renbing JIA . Relationship between histopathological features, Ki-67 expression and prognosis of conjunctival melanoma[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022 , 42(5) : 617 -623 . DOI: 10.3969/j.issn.1674-8115.2022.05.009

References

1 ZHOU C, WANG Y, JIA R, et al. Conjunctival melanoma in Chinese patients: local recurrence, metastasis, mortality, and comparisons with caucasian patients[J]. Invest Ophthalmol Vis Sci, 2017, 58(12): 5452-5459.
2 GRIMES J M, SHAH N V, SAMIE F H, et al. Conjunctival melanoma: current treatments and future options[J]. Am J Clin Dermatol, 2020, 21(3): 371-381.
3 JAIN P, FINGER P T, DAMATO B, et al. Multicenter, international assessment of the eighth edition of the American Joint Committee on Cancer: cancer staging manual for conjunctival melanoma[J]. JAMA Ophthalmol, 2019, 137(8): 905-911.
4 ESMAELI B, RUBIN M L, XU S Q, et al. Greater tumor thickness, ulceration, and positive sentinel lymph node are associated with worse prognosis in patients with conjunctival melanoma: implications for future AJCC classifications[J]. Am J Surg Pathol, 2019, 43(12): 1701-1710.
5 ESMAELI B, ROBERTS D, ROSS M, et al. Histologic features of conjunctival melanoma predictive of metastasis and death (an American Ophthalmological thesis)[J]. Trans Am Ophthalmol Soc, 2012, 110: 64-73.
6 MENON S S, GURUVAYOORAPPAN C, SAKTHIVEL K M, et al. Ki-67 protein as a tumour proliferation marker[J]. Clin Chimica Acta, 2019, 491: 39-45.
7 SCOLYER R A, RAWSON R V, GERSHENWALD J E, et al. Melanoma pathology reporting and staging[J]. Mod Pathol, 2020, 33(Suppl 1): 15-24.
8 JIA S, ZHU T, SHI H, et al. American Joint Committee on Cancer (AJCC) tumor staging system predicts the outcome and metastasis pattern in conjunctival melanoma[J]. Ophthalmology, 2022, S0161-6420(22)00168-3. DOI: 10.1016/j.ophtha.2022.02.029.
9 SHIELDS C L, SHIELDS J A. Tumors of the conjunctiva and cornea[J]. Indian J Ophthalmol, 2019, 67(12): 1930-1948.
10 SHIELDS C L, MARKOWITZ J S, BELINSKY I, et al. Conjunctival melanoma: outcomes based on tumor origin in 382 consecutive cases[J]. Ophthalmology, 2011, 118(2): 389-395.e1-2.
11 WONG J R, NANJI A A, GALOR A, et al. Management of conjunctival malignant melanoma: a review and update[J]. Expert Rev Ophthalmol, 2014, 9(3): 185-204.
12 KARIM R, CONWAY R M. Conservative resection and adjuvant plaque brachytherapy for early-stage conjunctival melanoma [J]. Clin Exp Ophthalmol, 2011, 39(4): 293-298.
13 FINGER P T, PAVLICK A C. Checkpoint inhibition immunotherapy for advanced local and systemic conjunctival melanoma: a clinical case series[J]. J Immunother Cancer, 2019, 7(1): 83.
14 THOMPSON J F, SOONG S J, BALCH C M, et al. Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database[J]. J Clin Oncol, 2011, 29(16): 2199-2205.
15 NAGARAJAN P, CURRY J L, NING J, et al. Tumor thickness and mitotic rate robustly predict melanoma-specific survival in patients with primary vulvar melanoma: a retrospective review of 100 cases[J]. Clin Cancer Res, 2017, 23(8): 2093-2104.
16 PI?ERO-MADRONA A, RUIZ-MERINO G, CEREZUELA FUENTES P, et al. Mitotic rate as an important prognostic factor in cutaneous malignant melanoma[J]. Clin Transl Oncol, 2019, 21(10): 1348-1356.
17 MAURICHI A, MICELI R, CAMERINI T, et al. Prediction of survival in patients with thin melanoma: results from a multi-institution study[J]. J Clin Oncol, 2014, 32(23): 2479-2485.
18 AIVAZIAN K, AHMED T, EL SHAROUNI M A, et al. Histological regression in melanoma: impact on sentinel lymph node status and survival[J]. Mod Pathol, 2021, 34(11): 1999-2008.
19 EL SHAROUNI M A, AIVAZIAN K, WITKAMP A J, et al. Association of histologic regression with a favorable outcome in patients with stage 1 and stage 2 cutaneous melanoma[J]. JAMA Dermatol, 2021, 157(2): 166-173.
20 BASTIAN B C. Hypothesis: a role for telomere crisis in spontaneous regression of melanoma[J]. Arch Dermatol, 2003, 139(5): 667-668.
21 SUN X M, KAUFMAN P D. Ki-67: more than a proliferation marker[J]. Chromosoma, 2018, 127(2): 175-186.
22 JAKOBIEC F A, BHAT P, COLBY K A. Immunohistochemical studies of conjunctival nevi and melanomas[J]. Arch Ophthalmol, 2010, 128(2): 174-183.
Options
Outlines

/

〈 〉